Leaders TECA Cooling Pad
Everything behind the verdicts on this product: the rule that fired for each concern, the three answers and the documents they rest on, every study on the row with the date it was opened, and the versions of the tables that produced them. Nothing here is edited by hand; it is generated from the same records the verdicts are.
The scaleRecommendedGoodSupportingEarly evidenceNot for thisAvoidhow it works
Engine 5.2.0 · rules 0.5.1 · evidence table ev-2026.10-r231 · computed October 13, 2026 · how we decide · the evidence table · the anchors
for Sensitivity
No fragrance, drying alcohol, declarable allergens or sensitising preservatives in this pad — the profile sensitive skin looks for.
For sensitivity only: no fragrance, drying alcohol, declarable allergens or sensitising preservatives in the formula.
- Rule
- F2 → Good choice. The formula carries no trigger and no caution for the concern.
q3 = gentle
Why this rule exists: Gentle = no weighted deduction fired and fit ≥ 90.
Rule F2 decided 1,955 verdicts across the catalog; “Good choice” is the verdict on 1,955 of 45,446. The full register. - Carrying active
- TECA
- 1 · Standing
- None
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.05%, from the trials on the row; needs leave-on contact - 3 · Tolerability
- Gentle
- Evidence dots
- Not from a trial row
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- The Effectiveness and Safety of a Skin Care Product With Centella asiatica Leaf Extract, Ceramide NP, and Panthenol in Subjects With Sensitive Skin: A Prospective, Observational Study — Journal of Cosmetic Dermatology (2025), opened July 16, 2026
- The Effects of a Standardized Extract of Centella asiatica on Postlaser Resurfacing Wound Healing on the Face: A Split-Face, Double-Blind, Randomized, Placebo-Controlled Trial — Journal of Alternative and Complementary Medicine (2020), opened July 16, 2026
← Back to the verdict All sensitivity products → Disclose a concentration or correct a fact →
for Post-Procedure
Allantoin has early or mechanistic evidence for post procedure — a reasonable bet, not a recommendation; the other actives here are not yet assessed for it.
The lead active has early or mechanistic evidence only, or is present below a working level. A reasonable bet, not a recommendation.
- Rule
- R9 → Unproven. An active with early or mechanistic evidence only; the product’s category job is not a recognised companion to the concern.
q1 = plausible · supportive = false
Why this rule exists: Plausible-tier actives alone do not earn a recommendation, and 'not for this' would overstate the case against them. 'Unproven' with the evidence dots lets the reader judge the bet (added 0.2.0 after the first shadow run put a 10% niacinamide serum at 'not for this' for hyperpigmentation). 0.5.0: the closing clause reads the other heroes — "nothing else here addresses it" only when every other active has a researched 'none' row; "not yet assessed" when that is the truth. Rows whose dots read moderate or better now reach R9p first.
Rule R9 decided 4,156 verdicts across the catalog; “Unproven” is the verdict on 4,156 of 45,446. The full register. - Carrying active
- Allantoin
- 1 · Standing
- Plausible — trials support it
- 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
Studied range: 0.5–2%, from the OTC monograph or label; needs leave-on contact - 3 · Tolerability
- Gentle
- Evidence dots
- Limited evidence
Row checked against its sources on July 17, 2026 (evidence table ev-2026.10-r231). - What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
The studies and documents on the row
- Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study) — Orphanet Journal of Rare Diseases (2020), opened July 17, 2026
← Back to the verdict All post-procedure products → Disclose a concentration or correct a fact →
for Dehydration
Nothing here targets dehydration directly; humectant hydration is the recognised companion to treating it, and this pad does that without known triggers.
Nothing here targets the concern directly, but the product’s job — barrier care, gentle cleansing, photoprotection — is the recognised companion to treating it. Rinse-off products carrying leave-on actives land here too.
- Rule
- R8 → Supporting role. An active with early or mechanistic evidence only or an active researched for the concern and found wanting or an active with no evidence row for the concern yet; the product’s category job is a recognised companion to treating the concern.
q1 = plausible | none | not-assessed · supportive = true
Why this rule exists: The category's job (barrier care, humectant hydration, gentle cleansing, photoprotection) is the documented supportive role for this concern. This is the honest verdict for a moisturizer on an acne page.
Rule R8 decided 3,793 verdicts across the catalog; “Supporting role” is the verdict on 7,796 of 45,446. The full register. - Carrying active
- Allantoin
- 1 · Standing
- Not assessed
No evidence row exists for this active and concern; it is in the research queue. - 2 · Form
- Plausible — concentration not declared; read from the position in the ingredient list
- 3 · Tolerability
- Gentle
- Evidence dots
- Not from a trial row
- What readers report
- No reviews read yet for this product. Shown beside the verdict; never blended into it.
- Verdict since
- September 5, 2026 (unchanged across rebuilds since then)
← Back to the verdict All dehydration products → Disclose a concentration or correct a fact →
as a toner
Does what a toner is for: not alcohol-driven, adds something real.
- Rule
- J2 → Does the job. The category-job reading is 65 or more.
Category job score over the measured features 65–85. - Measured from the label
- adds something real, not alcohol-driven
- Not measurable from the label
- restores skin pH, plays well with what follows
- Tolerability
- Gentle
Listed for Excess Oiliness, Compromised Skin Barrier, Rough Texture, with no verdict: the actives here have no evidence row for those concerns yet. That is a gap in our table, not a mark against the product.
- Excess Oiliness: The actives here (Allantoin, Guaiazulene, Centella Asiatica, Probiotics & Prebiotics) are in the research queue for excess oiliness; no verdict until their rows are written.
- Compromised Skin Barrier: The actives here (Allantoin, Guaiazulene, Centella Asiatica, Probiotics & Prebiotics) are in the research queue for compromised skin barrier; no verdict until their rows are written.
- Rough Texture: The actives here (Allantoin, Guaiazulene, Centella Asiatica, Probiotics & Prebiotics) are in the research queue for rough texture; no verdict until their rows are written.
- Fungal-acne triggers
A verdict is Dermington’s assessment of how well a product’s ingredients fit a concern — never a claim about what the product treats. Every rule is public and the same for every product; a brand cannot buy a reading. How we decide · what has changed · disclaimer.